LYNPARZA (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer

14.11.2022 - AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval ...

Related Keywords

China ,Japan ,United States ,Canada , ,Instagram ,Linkedin ,Twitter ,Statement Of Merck Co Inc ,Merck Co Inc ,Exchange Commission ,Astrazeneca ,Youtube ,European Union ,Facebook ,Merck Co Stock ,Acute Myeloid Leukemia ,Fetal Toxicity ,Thromboembolic Events ,First Line Maintenance ,Advanced Ovarian ,First Line Maintenance Advanced Ovarian Cancer ,Maintenance Recurrent Ovarian ,Adjuvant Treatment ,High Risk Early Breast ,Negative Metastatic Breast ,Metastatic Pancreatic ,Metastatic Castration Resistant Prostate ,Positive Advanced Ovarian Cancer ,Line Maintenance ,Prescribing Information ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Merck Amp Co ,